European Psychiatric Association (EPA) comprehensive review demonstrates that exercise is an effective treatment for major mental health conditions and should form a core part of treatment
Philadelphia, October 1, 2018
Based on compelling evidence from a meta-review of existing research, the European Psychiatric Association (EPA) has issued new guidelines to promote exercise as a key additional treatment for mental health conditions. A global team of scientists collaborated on the new EPA guidelines published in European Psychiatry, which suggest a regime of structured exercise should be added to standard medication and psychotherapy. The authors found that exercise can effectively reduce mental health symptoms, improve cognition, and strengthen cardiovascular fitness among patients with depression and schizophrenia.
Their analysis, issued as the EPA’s position statement and guidelines, demonstrates that moderate intensity aerobic exercise, two to three times a week for at least 150 minutes, reduces symptoms of depression and schizophrenia and improves cognition and cardiorespiratory health in schizophrenia spectrum disorders. Evidence also supports combining aerobic with resistance exercise to improve outcomes for individuals with schizophrenia spectrum disorders and major depression.
The EPA guidance was also endorsed by the International Organization of Physical Therapists in Mental Health (IOPTMH). The multidisciplinary team of experts in physiotherapy, psychiatry, psychology, and sports medicine conducted a systematic review of top-tier research around exercise for mental health.
“Our comprehensive review provides clear evidence that physical activity has a central role in reducing the burden of mental health symptoms in people with depression and schizophrenia. Our guidelines provide direction for future clinical practice. Specifically, we provide convincing evidence that it is now time for professionally-delivered physical activity interventions to move from the fringes of healthcare and become a core component in the treatment of mental health conditions,” explained lead investigator Brendon Stubbs, PhD, Institute of Psychiatry, Psychology & Neuroscience, King’s College London, and South London and Maudsley NHS Foundation Trust, London, UK.
Long-term outcomes and full recovery among people with mental illness are often poor, even for those receiving appropriate medications. People with mental illness also experience very poor physical health and drastic physical health inequalities, which lead to this population dying up to twenty years prematurely.
“Signs and symptoms of premature cardiovascular diseases can be identified early in the disease course of mental disorders, when patients are in their thirties to forties,” commented senior-author Kai G. Kahl, PhD, Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Germany. “Interventions that modify cardiometabolic risks are clearly needed, and should be recommended as early as possible, as an integral part of a multimodal treatment plan.” Thus, new add-on treatments for mental illness that can support full recovery and address poor physical health are urgently needed. The guidance advocates the development of structural changes in hospitals and other institutions concerned with the treatment of mental disorders that establish exercise facilities and physiotherapists or exercise specialists to support the treatment of severe mental illness. It also points to the need to modify insurance reimbursement guidelines to include the recommended treatments.
This initiative began with Dr. Stubbs’ discussions with co-investigators Prof. Hans-Jürgen Möller, MD, PhD, Department of Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, Germany, and Prof. Dr. Kahl, who were among the authors of the first EPA position statement on cardiovascular disease and diabetes in people with severe mental illnesses. Issued in 2009, the authors recommended screening and treating cardiovascular risk factors and diabetes in patients with mental illness. “The current EPA position statement on exercise in mental illness can be seen as a sequel to this first EPA position statement,” Prof. Dr. Kahl noted.
This study provides evidence that physical activity plays an important role in reducing cardiovascular symptoms and improving physical health and fitness. “Our systematic review of top-tier evidence has convincingly demonstrated that exercise training, delivered by physical activity professionals, does indeed provide an effective add-on treatment for improving both physical and mental health outcomes in people with mental illness,” said Dr. Stubbs.
Additional research on the effect of exercise therapy on patients with bipolar disorder, on anthropometric measures (such as BMI), as well as its long-term impact and cost-effectiveness is recommended. Understanding the neurobiological mechanism by which exercise affects mental health and the potential impact of sedentary behaviors on mental health are also important subjects for future study.
Notes for editors
The article is “EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Mental Health (IOPTMH),” by Brendon Stubbs, Davy Vancampfort, Mats Hallgren, Joseph Firth, Nicola Veronese, Marco Solmi, Serge Brand, Joachim Cordes, Berend Malchow, Markus Gerber, Andrea Schmitt, Christoph U. Correll, Marc De Hert, Fiona Gaughran, Frank Schneider, Florence Kinnafick, Peter Falkai, Hans-Jürgen Möller, and Kai G. Kahl (http://dx.doi.org/10.1016/j.eurpsy.2018.07.004). It appears in European Psychiatry, volume 54 (October 2018) published by Elsevier.
This research was supported by the Maudsley Charity and the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) South London, where Brendon Stubbs works as part of a research team investigating ways to help people with severe mental illness to improve their physical health. Brendon Stubbs also holds a Clinical Lectureship supported by Health Education England and the NIHR Integrated Clinical Academic (ICA) Programme (ICA-CL-2017-03-001). The views expressed in the publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Full text of this article is available to credentialed journalists upon request; contact Damon Mastandrea at +1 215 239 3555 or firstname.lastname@example.org. Journalists who wish to interview the authors should contact Brendon Stubbs at +44 203 228 3877, +44 7834 147 327 (mobile), or email@example.com.
About European Psychiatry
European Psychiatry is the official journal of the European Psychiatric Association (EPA), the largest international association of psychiatrists in Europe. The purpose of the EPA is to improve the lives of patients with psychiatric disorders and to promote professional excellence through education and research. European Psychiatry supports the mission of the EPA and publishes articles on topics relevant to all mental health clinicians, researchers, and neuroscientists. www.europsy-journal.com
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. www.elsevier.com
+1 215 239 3555